This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
TechCrunch
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from TechCrunch.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How coverage developed
First report from TechCrunch
Story updateHeadline updated
How CurrentWire compiled this story
TechCrunch (techcrunch.com), a Tier B publisher, filed this report on . CurrentWire published this page 23 minutes later, on .
Filed under Technology · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Artificial Intelligence (38), Vijay Pande (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.